Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE R IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Fluid and electrolyte replacement for maintenance or restoration,Treatment of mild to moderate metabolic acidosis
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion at a rate of 25-50 m L/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable (Plasma-Lyte R components are endogenous electrolytes and water; administered crystalloid redistributes rapidly; half-life of approximately 20-30 minutes for volume expansion due to renal excretion and redistribution into interstitial space)
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Not metabolized; acetate and gluconate are metabolized to bicarbonate in the liver and peripheral tissues.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal: >90% (electrolytes and water); Biliary/fecal: negligible (<5%)
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Minimal (<5%); ions remain free in solution
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Approximately 0.25-0.3 L/kg (limited to extracellular fluid compartment; distributes primarily in plasma and interstitial fluid)
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100%
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
Contraindicated in severe renal impairment (creatinine clearance < 30 m L/min) due to risk of hyperkalemia and fluid overload. For mild-to-moderate impairment (Cr Cl 30-89 m L/min), reduce infusion rate by 25-50% and monitor serum potassium.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
Child-Pugh Class A: No adjustment. Child-Pugh B: Reduce infusion rate by 25% and monitor for fluid overload. Child-Pugh C: Avoid use due to risk of exacerbating ascites and electrolyte imbalances.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Weight-based dosing: 20-100 m L/kg/day as a continuous infusion, with rate not exceeding 50 m L/kg/hour. Adjust based on hydration status, serum electrolytes, and renal function.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Initiate at low end of dosing range (e.g., 25-30 m L/kg/day) due to age-related renal decline and increased risk of fluid overload. Monitor serum potassium, creatinine, and fluid balance closely.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
None.
None
Use with caution in patients with heart failure, renal impairment, or conditions with sodium retention,Monitor serum electrolytes and fluid balance,Risk of hypervolemia,Do not use if solution contains precipitate or if container is damaged
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hypernatremia,Hyperchloremia,Metabolic alkalosis,Severe renal impairment with oliguria,Hypersensitivity to any component
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No known food interactions. However, patients on a sodium- or potassium-restricted diet should consult their physician before receiving this solution.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No fetal risk identified in any trimester when used as indicated.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Compatible with breastfeeding. The components are normal blood constituents; no excretion into milk expected. M/P ratio not applicable; no risk to nursing infant.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No dose adjustment required. Pregnancy does not alter pharmacokinetics of crystalloid solutions; administer based on clinical need for fluid and electrolyte replacement.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
Plasma-Lyte R is an isotonic crystalloid solution used for fluid and electrolyte resuscitation. It contains acetate and gluconate as buffers, which may be preferable in patients with lactic acidosis or hepatic dysfunction. Rapid infusion can cause volume overload; monitor renal function and serum electrolytes. Not recommended for patients with preexisting hyperkalemia.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
Inform your healthcare provider if you have kidney problems, heart failure, or are on a sodium-restricted diet.,Report any signs of fluid overload, such as shortness of breath, swelling in the ankles or feet, or sudden weight gain.,This solution contains potassium; avoid potassium supplements or salt substitutes unless directed by your doctor.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE R IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE R IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte R provides electrolytes and water to maintain or restore fluid balance, with bicarbonate precursors (acetate, gluconate) to buffer metabolic acidosis.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE R IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE R IN PLASTIC CONTAINER is: Intravenous infusion at a rate of 25-50 m L/kg body weight per 24 hours, adjusted for fluid and electrolyte needs. Typical adult maintenance dose: 1-2 L/day.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE R IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE R IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity. Plasma-Lyte R is an isotonic crystalloid solution; components (sodium, potassium, magnesium, chloride, acetate, gluconate) are physiological ions. No. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.